March 23, 2023–(BUSINESS WIRE)–Cala, the bioelectronic medicine leader setting a new standard of care for chronic disease, today announced meeting the primary endpoint on an interim analysis of a prospective, randomized, controlled study. This study, “RWE Study Utilizing the Cala Trio Device in Patients With Essential Tremor” (clinicaltrials.gov NCT05540626), demonstrated that adding TAPS therapy to […]
Cala Trio continues to be an effective therapy for managing essential tremor, according to a recently released study by Cala Health. Liana Hennum, head of health economics outcomes research for Cala, talks about other positive outcomes revealed in this study.
BURLINGAME, Calif.–(BUSINESS WIRE)–Cala Health, a bioelectronic medicine company developing wearable therapies for chronic disease, announces two validating pieces of news for the non-invasive prescription therapy for essential tremor (ET), Cala Trio™. Real-world evidence of a Veteran Affairs (VA) patient population presented at The International Parkinson and Movement Disorder Society (MDS) 2021 virtual congress on September 15 showcases Cala […]
BURLINGAME, Calif.–(BUSINESS WIRE)–Cala Health, Inc., a bioelectronic medicine company developing wearable therapies for chronic disease, today reported data demonstrating the increasing prevalence of essential tremor (ET) from 2010 to 2018; a high rate of depression and anxiety in patients with ET; and the safety and efficacy of Cala Trio when used in a real-world setting […]
Bioelectronic company Cala Health released positive data from its ongoing PROSPECT trial demonstrating that a majority of patients using its FDA-cleared Cala Trio device reported a reduction in hand tremors.